西藏诺迪康药业股份有限公司关于以集中竞价方式回购股份的回购报告书

Core Viewpoint - The company plans to repurchase shares with a total amount between RMB 170 million and RMB 200 million to enhance employee motivation and align interests among shareholders, the company, and employees [2][8]. Summary by Sections Repurchase Plan Overview - The repurchase will utilize the company's own funds and is intended for employee stock ownership plans or equity incentives [3][13]. - The maximum repurchase price is set at RMB 55 per share, which is 150% of the average trading price over the last 30 trading days prior to the board's decision [3][12]. - The repurchase will be conducted through centralized bidding on the Shanghai Stock Exchange and will last no longer than 12 months from the board's approval date [4][8]. Financial Impact - As of September 30, 2025, the company's total assets are RMB 5.816 billion, with net assets of RMB 3.551 billion and current assets of RMB 4.146 billion. The planned repurchase amount represents approximately 3.44% of total assets, 5.63% of net assets, and 4.82% of current assets [14]. Implementation Conditions - The repurchase period may end early if the maximum funding limit is reached or if the board decides to terminate the plan [9]. - The company will not repurchase shares during periods that could significantly impact stock prices or as dictated by regulatory requirements [10]. Shareholder Considerations - There are no plans for share reductions by major shareholders, including directors and senior management, in the next three to six months [4][15]. - The company will ensure that the repurchased shares are used for the intended purposes within the legal timeframe; otherwise, unallocated shares will be canceled [12][16]. Regulatory Compliance - The company has established a dedicated securities account for the repurchase and will comply with all relevant regulations and disclosure requirements throughout the process [20].